Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.
The Details:
Bio-Path said the data presented showed prexigebersen continues to be well-tolerated and demonstrated efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
“It was a pleasure to present these compelling data to an ...